Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|Metastatic Triple Negative Breast Cancer
Interventions: DRUG: NK012 and carboplatin
Sponsor: Nippon Kayaku Co., Ltd.